The new lots further enhance Lonza’s renowned human primary cell offerings as it looks to meet growing market demand for deeper cell characterization
Test adds to QIAGEN’s growing portfolio of PCR testing solutions for COVID-19 testing
QIAreach SARS-CoV-2 Antigen Test is an important step towards decentralized mass screening by processing samples in 2–15 minutes
Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide
Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability
The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post symptom onset and post positive PCR
Underscores importance of serological testing using the S1 subunit for worldwide seroprevalence and vaccine development
Study by University of Manchester reassures patients that it is safe to take blood pressure medication during the pandemic
New kit aims to provide highly sensitive and efficient approach for studying mitophagy impairment in conditions such as Parkinson’s and Alzheimer’s
Proven, scalable platform aims to increase dose yields and reduces process development time for cell and gene therapies
Veklury is first FDA-approved treatment for COVID-19 in the US, and aims to shorten time to recovery by five days
The hypercube algorithm aims to enable regular, cost-effective screening in multiple contexts
The TaqPath test is authorized for use with the Everlywell COVID-19 Test Home Collection Kit, which enables individuals to self-collect nasal swab specimens
Watch this on-demand webinar to learn how to perform untargeted/semi-targeted metabolomic studies to discover novel biomarkers by mass spectrometry
The partnership aims to expand existing Monocyte Distribution Width (MDW) hematology-based biomarker to potentially aid in the rapid detection of MIS-C
The test uses a convolutional neural network to classify microscopy images of single intact particles of different viruses
Availability of the new IgM blood test on the ARCHITECT and Alinity platforms is part of Abbott's effort to offer tests across the disease progression of COVID-19
Easy-to-use test, which doesn't require specialized laboratory personnel or instruments, promises flexibility to test in locations that benefit from immediate results
The CTS Rotea system aims to help researchers overcome manufacturing hurdles and bring the vast potential of cell therapies to more patients
Antibodies available are specific for S1, S2 and receptor-binding domain regions of SARS-CoV-2 Spike protein
Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season
The Phase II clinical trial, which will use cutting-edge CRISPR genetic engineering, has already begun enrolling patients
The addition of COVID-19 antibody tests to the portfolio aims to further support the pandemic response on multiple fronts
Access SARS-CoV-2 IgG assay shows excellent agreement with the Genscript Surrogate Virus Neutralization Test
